title: Can we still learn from single center experience after PARTNER?
abstract: With the publication of the Placement of Aortic Transcatheter Valves (PARTNER) trial, transcatheter aortic valve replacement (TAVR) has undoubtedly become the gold standard for severe aortic stenosis in patients that are not suitable candidate for surgical aortic valve replacement (AVR). The PARTNER trial also showed that TAVR is non-inferior to AVR in high-risk patients. A recent publication by Ben-Dor et al evaluated the outcome of high-risk patients with severe aortic stenosis who were referred to their institution for participation to the PARTNER trial. Only a minority of patients made it in the trial and the majority of patient ended being treated medically. Some patients were also treated with AVR outside the trial. The outcomes of all these patients were stratified by the treatment they received (AVR, TAVR or medical therapy with or without balloon aortic valvuloplasty). The 3 groups were different in their baseline characteristics. Ben-Dor et al found that patients treated medically had greater mortality than patients treated with TAVR or AVR. The survival of patients treated with TAVR was similar to those treated with AVR. Independent predictors of mortality were also found from their analysis. In this commentary, we discuss the finding of this study and compare it with the current literature.
authors.affiliation: Benoit Daneault, Tamas Z Fulop, Paul Farand, Division of Cardiology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
authors.forename: Benoit
authors.initials: B
authors.lastname: Daneault
authors.forename: Tamas Z
authors.initials: TZ
authors.lastname: Fulop
authors.forename: Paul
authors.initials: P
authors.lastname: Farand
keywords: Aortic stenosis; Aortic valve replacement; Balloon aortic valvuloplasty; Transcatheter aortic valve replacement
references.citation: Eur Heart J. 2010 Apr;31(7):865-74
references.pmid: 20037180
references.citation: N Engl J Med. 2010 Oct 21;363(17):1597-607
references.pmid: 20961243
references.citation: J Am Coll Cardiol. 2010 Mar 16;55(11):1080-90
references.pmid: 20096533
references.citation: J Am Soc Nephrol. 2004 Jun;15(6):1597-605
references.pmid: 15153571
references.citation: J Am Coll Cardiol. 2012 Oct 9;60(15):1438-54
references.pmid: 23036636
references.citation: J Am Coll Cardiol. 2010 Nov 9;56(20):1668-76
references.pmid: 21050978
references.citation: J Am Coll Cardiol. 2012 Jun 19;59(25):2317-26
references.pmid: 22503058
references.citation: J Am Coll Cardiol. 2011 Nov 8;58(20):2130-8
references.pmid: 22019110
references.citation: Am J Cardiol. 2012 Oct 1;110(7):1008-14
references.pmid: 22721576
references.citation: N Engl J Med. 2011 Jun 9;364(23):2187-98
references.pmid: 21639811
references.citation: Eur Heart J. 2003 Jul;24(13):1231-43
references.pmid: 12831818
references.citation: N Engl J Med. 2012 May 3;366(18):1705-15
references.pmid: 22551129
references.citation: Eur Heart J. 2012 Oct;33(19):2388-98
references.pmid: 22851654
references.citation: JACC Cardiovasc Interv. 2010 Nov;3(11):1141-9
references.pmid: 21087750